We added the following clinical trials to Metastatic Trial Search for July/ August 2024. To see all clinical trials, please visit Metastatic Trial Search.
ER or PR Positive Trials
- Sacituzumab Govitecan ADC After T-DXd ADC for Advanced HR+, HER2 Low Breast Cancer
- Blood Test to Predict Response to Treatment for Women with Metastatic HR+ Breast Cancer
- Sacituzumab Tirumotecan ADC for Advanced HR+, HER2- Breast Cancer
- Studying a New Order of Giving Currently Approved Drugs for Women with HR+, HER2- Breast Cancer
HER2 Positive Trials
HER2 Negative Trials
Triple Negative Trials
- ZM008 Targeted Therapy Alone or With Pembrolizumab for Advanced Triple Negative Breast Cancer
- PBA-0405 Targeted Therapy for Stage I-IV Triple Negative Breast Cancer
- Dato-DXd ADC With or Without Durvalumab Immunotherapy for Advanced Triple Negative, PD-L1 Positive Breast Cancer
- AGX101 ADC for Advanced Triple Negative Breast Cancer
- LY4170156 ADC for Advanced Triple Negative Breast Cancer
Other Stage IV Trials
- Care and Monitoring at Home for People with Brain Metastasis
- Developing a Nervous System Exam for People With Leptomeningeal Metastasis
Last Modified on July 1, 2024